DRMA — Q2 2026 Financial Report Analysis

Dermata Therapeutics has stopped being a drug developer. It began as a biotech testing prescription acne treatments made from Spongilla lacustris, a freshwater sponge ground into a fine powder. In September 2025 it switched to selling cosmetic skincare directly to consumers under the Tome brand, starting with the "Foundational Treatment": four once-weekly treatments for $178, which the company planned to start selling on August 25, 2026. Q2 2026 is the last quarter before that launch, and the numbers show what the switch costs. Net loss widened 74% to $2.97 million because selling, general and administrative (SG&A) spending more than doubled to $2.80 million, while research spending fell by about two-thirds. Dermata still has no revenue. It ended June with $4.4 million in cash, which management said would last only "into the fourth quarter of 2026." The company also carries a going-concern warning and is being sued by the sponge supplier it used to license from.

The quarter in numbers

Operating margin (operating profit as a share of revenue) isn't shown because there is no revenue to divide by. All $3.01 million of operating costs flowed straight into the loss. The only offset was $47,000 of interest earned on cash, down from $72,000 because there was less cash.

Compared with the previous quarter the step-up is just as sharp: Q1 2026's net loss was $1.85 million, so Q2's loss was about 61% bigger.

Takeaway: Dermata has replaced a slow, expensive drug-approval path with a fast but cash-hungry consumer launch, and it had less than two quarters of cash at June 30 to show the change works. Over the next few quarters, what matters is whether Tome sales cover a growing marketing budget before the next share sale. Each round of new shares cuts existing holders' slice of the company: the share count has risen more than sixfold in a year.

Where the money went

Research and development fell to $0.21 million from $0.62 million. The filing says this is because the company decided "to prioritize the commercial launch of its first product." For the half year, R&D fell by $1.3 million: $0.6 million because the STAR-1 acne study, the late-stage trial of its former prescription candidate, finished in Q2 2025, and $0.7 million from cutting back other research. Management expects R&D to keep falling. The planned Phase 2a trial with Revance, which would have tested the sponge powder as a way to get Revance's botulinum toxin (Daxxify) into the skin without needles, "has placed... on hold."

SG&A is now the business. Besides the marketing, legal and pay increases above, about $0.4 million of Q2 marketing spend ($0.6 million for the half) went to Reunion, the branding agency designing the Tome launch. Its founding partner is the CEO's son-in-law. The board and audit committee approved the arrangement under the company's related-party policy, and the filing discloses it. Still, readers should know that a meaningful share of the launch budget goes to a family connection of management. Management expects SG&A to "continue to increase related to marketing, branding, advertising, and personnel expenses."

What the headline numbers hide

• Cash runway was short even before launch spending rises. Operating cash burn (cash actually spent running the business) was $2.48 million in Q1 and about $2.42 million in Q2: the six-month total of $4.90 million minus Q1's figure. Including equipment purchases, cash fell by $2.53 million in Q2, from $6.95 million to $4.41 million. That is about 1.7 quarters of runway at June 30, which matches management's "into the fourth quarter of 2026."
• Q2 cash burn was flattered by unpaid bills. Accounts payable rose to $1.12 million from $0.46 million at year-end. Six-month operating cash use ($4.90 million) was only slightly higher than the net loss ($4.81 million), partly because about $0.73 million more was owed to suppliers. Those bills still have to be paid, so the real burn rate is closer to the roughly $3 million quarterly loss than the $2.4 million cash figure.
• One-off and lumpy items. About $0.7 million of the Q2 legal bill came from the Villani litigation. That may not repeat at the same size, but the case is still open. Six-month interest income was slightly higher ($125,000 vs $108,000) only because of interest on an Employee Retention Tax Credit refund received in Q1. In Q2 alone, interest income fell. The company also accrued a settlement offer on a liquidated-damages claim tied to its registration-rights agreements. The amount is not broken out.
• Dilution has been steep and continued after quarter-end. Shares outstanding rose from 637,757 at June 30, 2025 to 4,022,143 at June 30, 2026, after a 1-for-10 reverse split in August 2025, a December 2025 private placement (net $3.8 million), and $2.0 million raised by selling shares on the market (an "ATM" program) in January 2026, which used up all remaining ATM capacity. On August 16, 2026, after the quarter, Dermata agreed another private placement at $1.46 per share: 933,064 shares plus pre-funded warrants for 1,360,544 more (warrants that cost $0.001 each to exercise), for estimated net proceeds of about $3.2 million. That alone adds about 2.29 million shares, roughly 57% more than were outstanding at June 30. Insiders, including the CEO and CFO, put in about $2.4 million of the roughly $3.4 million gross, so outside investors provided less than a third.
• Another 10 million shares could follow from warrants. At June 30 there were warrants for 5.42 million shares outstanding, all priced above that day's $1.29 share price. The August deal added Series E and F warrants for another 4.59 million shares at $1.46–$1.47. If these are exercised, the company gets cash but the shareholder base grows again.
• Our rough runway estimate after the August raise: $4.4 million plus about $3.2 million gives roughly $7.6 million before July and August spending. At Q2's loss rate of about $3 million a quarter, that lasts about 2.5 quarters from mid-year, into early 2027. Management says marketing costs will rise, though, and that it "will need to raise additional capital to sustain operations." So the gap until the next raise is likely shorter than that. This is our calculation, not company guidance. The going-concern warning in the 10-Q was written before the August raise.

The legal overhang

Dermata ended its sponge license with Villani, Inc., effective February 15, 2026, after Villani accused it of breaching the agreement by leaving prescription development. Villani sued in April 2026 in federal court in California, alleging false advertising, breach of contract and conversion (taking property that isn't yours). In June it also started an arbitration case seeking money damages. In May the court temporarily limited some of Dermata's marketing claims. On August 5, 2026 the court denied Villani's request for a preliminary injunction (a court order to stop Dermata before trial) in full and lifted those limits. The judge found Villani unlikely to win its false-advertising and conversion claims, but said questions remain on the breach-of-contract claim. Dermata has not set aside any money for a possible loss and says it cannot estimate one. Villani can still seek a permanent injunction or win damages in arbitration. Dermata also says the dispute may make raising money harder.

Outlook

Management gave no revenue or sales guidance. The concrete milestones are:

• The Tome launch (planned for August 25, 2026, with waitlist pre-orders first). The Q3 10-Q, due around mid-November, will be the first filing that can show any sales. At $178 per four-week kit, covering a roughly $3 million quarterly loss would take about 17,000 kits a quarter at full retail price, before counting the cost of making and shipping them. Q3 revenue will show how far away that is.
• Spending direction: R&D lower, SG&A higher. Expect the quarterly loss to grow during launch.
• More products: a milder version for sensitive skin, a professional channel through aestheticians and dermatologists, and an OTC acne kit named as a use of the August proceeds. No timelines were given. The botulinum-toxin delivery idea has no launch timeline either.
• Financing: another raise looks likely within a few quarters unless launch sales come in well above what a brand-new consumer brand typically does. Watch for a new ATM program or another private placement, and for the stockholder vote needed to make the August warrants exercisable.

Our view: Q2 shows a company that has spent heavily to get to launch day, with little cash left and an open lawsuit. The change of strategy is clear and the product is real, but there is not yet any sales evidence that it works. The Q3 report is when that evidence starts to appear, and it matters more than anything in this quarter's numbers.